Last reviewed · How we verify
Standard of Care Chemotherapy
Standard of Care Chemotherapy works by interfering with the growth of cancer cells, ultimately leading to cell death.
Standard of Care Chemotherapy works by interfering with the growth of cancer cells, ultimately leading to cell death. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | Standard of Care Chemotherapy |
|---|---|
| Also known as | Investigator's choice of of standard regimen, Carboplatin, Paciltaxel, Cisplatin, Vinorelbine |
| Sponsor | Prothena Biosciences Ltd. |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Standard of Care Chemotherapy is a type of systemic therapy that targets rapidly dividing cells, such as cancer cells. It can be administered through various routes, including intravenous, oral, or topical application, and can be used in combination with other treatments to enhance its effectiveness.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Nausea
- Fatigue
- Hair loss
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer (NA)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Prospective Validation of Ataraxis AI Test for Predicting Treatment Response in Neoadjuvant Breast Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care Chemotherapy CI brief — competitive landscape report
- Standard of Care Chemotherapy updates RSS · CI watch RSS
- Prothena Biosciences Ltd. portfolio CI